Market Closed -
Nasdaq
16:00:00 2024-05-14 EDT
5-day change
1st Jan Change
20.36
USD
-4.59%
-16.01%
-4.10%
Presentation Operator MessageOperator (Operator)Ladies and gentlemen, thank you for standing b...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating
05-10
MT
Earnings Flash (XNCR) XENCOR Reports Q1 Revenue $12.8M
05-09
MT
Xencor, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-09
CI
BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating
04-16
MT
Xencor Names Bart Cornelissen as Chief Financial Officer
04-09
MT
Xencor, Inc. Announces CFO Changes
04-09
CI
Xencor Appoints Bart Cornelissen as Senior Vice President
04-09
CI
Transcript : Xencor, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:15 AM
03-14
Xencor Insider Sold Shares Worth $293,519, According to a Recent SEC Filing
03-07
MT
North American Morning Briefing : Fed's Preferred -2-
02-29
DJ
Wedbush Adjusts Xencor's Price Target to $34 From $36, Keeps Outperform Rating
02-28
MT
Transcript : Xencor, Inc., Q4 2023 Earnings Call, Feb 27, 2024
02-27
Earnings Flash (XNCR) XENCOR Posts Q4 Revenue $44.7M, vs. Street Est of $74.7M
02-27
MT
Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
02-27
CI
Xencor Insider Sold Shares Worth $1,048,743, According to a Recent SEC Filing
02-14
MT
Transcript : Xencor, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
01-10
Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy
01-02
CI
Xencor Insider Sold Shares Worth $941,670, According to a Recent SEC Filing
12-29
MT
Xencor, Inc. Enters into an Amended and Restated Collaboration and License Agreement with Genentech, Inc
11-15
CI
RBC Cuts Price Target on Xencor to $32 From $36, Keeps Outperform, Speculative Risk
11-08
MT
Wedbush Trims Xencor's PT to $36 From $37 After Stopping XmAb104 Development, Opting Out of Cost Sharing With Genentech to Co-develop XmAb306; Maintains Outperform Rating
11-08
MT
Transcript : Xencor, Inc., Q3 2023 Earnings Call, Nov 07, 2023
11-07
Earnings Flash (XNCR) XENCOR Reports Q3 Revenue $59.2M, vs. Street Est of $30M
11-07
MT
Xencor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-07
CI
Xencor, Inc. and OCM Life Sciences Portfolio LP, Entere into A Royalty Purchase Agreement
11-07
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
More about the company
Last Close Price
20.36
USD
Average target price
35.92
USD
Spread / Average Target
+76.41%
Consensus
1st Jan change
Capi.
-4.10% 1.32B +5.33% 111B +12.11% 105B -12.56% 22.34B -3.70% 21.93B -6.03% 18.59B -35.21% 18.12B -10.86% 16.96B +5.10% 13.7B +37.57% 12.45B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1